Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From IASLC
Focused radiation to the main tumor benefits certain metastatic lung cancer patients, especially those with specific mutations.
This IASLC consensus evaluates definitive-dose radiotherapy to the primary tumor in metastatic NSCLC. Strongest evidence supports RT in EGFR-mutant oligometastatic disease, with emerging data on dose escalation for other populations.
What the study was
- Study design
- Consensus statement / evidence synthesis
- Population
- Stage IV NSCLC patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Thoracic Oncology
Why it surfaced
Important consensus statement from IASLC with practice implications, but review/guideline format.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.